Novavax secures a non-exclusive licensing deal with Pfizer, validating Matrix-M's platform value and shifting NVAX toward a technology provider model. NVAX receives $30M upfront, a potential $500M in ...

After shedding expensive commercial infrastructure and pivoting to a partnership model, the company is now positioning its Matrix-M vaccine adjuvant as a versatile, license-ready asset for other ...

CONSHOHOCKEN, PA — Madrigal Pharmaceuticals Inc. (NASDAQ: MDGL) moved to tighten its grip on one of biotech’s hottest disease areas, striking a $50.00 million licensing deal with Pfizer that could ...

SHANGHAI, Feb 24 (Reuters) - Pfizer (PFE) has entered an agreement to license Sciwind Biosciences' type 2 diabetes treatment ‌ecnoglutide, with potential payments of up to $495 million ‌if milestones ...

NEW YORK(AP) — U.S. pharmaceutical giant Pfizer signed a deal to purchase development-stage obesity drugmaker Metsera Inc., winning a bidding war against Novo Nordisk, the Danish drugmaker behind ...

(Reuters) - Pfizer Inc, beating out numerous other bidders, said it agreed to buy U.S. cancer drug company Medivation Inc for $14 billion in cash, adding its blockbuster prostate cancer drug Xtandi to ...

AbbVie (NYSE:ABBV | ABBV Price Prediction) and Pfizer (NYSE:PFE) both reported fourth quarter earnings in early February.

Shares of Pfizer, the Indian arm of U.S.-based Pfizer Inc., rose more than 2% on Wednesday after President Donald Trump announced a deal with the drugmaker to provide key prescription medications at ...

Pfizer is behind Eli Lilly and Novo Nordisk in the GLP-1 race, but long-term investors shouldn't count the company out.